SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lupus drug belimumab tested in Real-World setting to see if it prevents organ damage
Disease control Recruiting nowThis study looks at whether belimumab, a drug for lupus, can reduce the risk of major organ flares in people with systemic lupus erythematosus (SLE). Researchers will compare patients taking belimumab to those on standard care using real-world data from Greece. The goal is to see…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Biomedical Research Foundation, Academy of Athens • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Tiny trial hopes to tame lupus and more with experimental biologic
Disease control Recruiting nowThis early-phase study tests a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that hasn't responded to standard treatments. The main goal is to check safety and find the right dose, with a secondary look at whether it helps control the diseas…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Immune cell therapy shows promise for tough lupus cases
Disease control Recruiting nowThis early-stage trial tests a treatment called MB-CART19.1, which uses a patient's own immune cells modified to target and destroy faulty B cells that drive lupus. It enrolls 29 adults with severe lupus that hasn't responded to standard therapies. The goal is to find a safe dose…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Could cord blood cells tame tough lupus?
Disease control Recruiting nowThis early-stage trial tests a new treatment made from donated umbilical cord blood cells, designed to target and calm the overactive immune system in adults with severe lupus that hasn't responded to standard therapies. About 48 participants will receive the therapy to see if it…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New lupus drug candidate enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to check safety and how the body handles the drug, not to cure the disease. Participants will receive either CC312 or a placebo, and researchers will monitor side eff…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC